Emerging Evidence of Brain Tissue Invasion by Hepatitis C Virus  

It has been reported that hepatitis C virus (HCV) infection is associated with cognitive dysfunction, fatigue and psychological disorders (e.g., depression), which do not correlate with the severity of liver disease and cannot be accounted for by hepatic encephalopathy or drug abuse.

There is also emerging evidence that HCV infection can have negative neurocognitive effects in HIV cohorts. Magnetic resonance spectroscopy has suggested the likely existence of a biological basis for these effects.

HCV replicative forms have recently been detected in autopsy brain tissue and the infected cells have been identified as CD68-positive (macrophages/microglia).

These findings raise the possibility that HCV infection of the brain could be directly related to the reported neuropsychological and cognitive changes.

HCV is not strictly hepatotropic, as it can also replicate in leukocytes, including monocytes/macrophages.

The latter cells could provide access of HCV into the central nervous system ('Trojan horse' mechanism) in a process similar to that postulated for HIV-1.

In support of this hypothetical mechanism come reports showing a close relationship between HCV sequences present in the brain and cerebrospinal fluid and sequences found in lymph nodes and peripheral blood mononuclear cells.

However, despite some similarities there is a fundamental difference between HIV-1 and HCV infection as the latter does not progress into AIDS-type dementia.

From the Department of Medicine, Mayo Clinic Scottsdale, Scottsdale, Arizona,Institute of Infectious Diseases, Warsaw Medical Academy, Poland, Barrow Neurological Institute, Phoenix, Arizona.

11/09/05

Reference
T Laskus and others. Emerging evidence of hepatitis C virus neuroinvasion. AIDS 19(Suppl 3): S140-144. October 2005.

 

FDA-approved Monotherapies for HCV
Intron A
Roferon

Infergen

Pegasys

PEG-Intron
FDA-approved
Combination
Therapies
for HCV
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
All HCV Topics  [ A to Z ]

2-log Drop
Acute (Primary) HCV Infection
Age
Alcohol / Smoking / Diabetes
ALT
Anemia
Children
Chronic HCV Infection
Clinical Trials
Cirrhosis
Cognitive Behavioral Therapy
Complementary Therapies (CAM)
Combination Treatment
Cryoglobulinemia /
Cryoglobulin

Disease Progression
Decompensation
Developing Countries
Depression
Diabetes Mellitus
Dose Reductions for
Interferon / Ribavirin

Drug Abuse
Drug Pricing

Drug Related Adverse Events
Early Treatment Cessation
Early Virologic Response

Epidemiology / African Americans
Epoetin Alpha
Early Viral Response (EVR)
Eradication
Extrahepatic Events
Experimental Treatment
Experimental Therapy (procedure)
Fibrosis
Gender
Genetics
Genotype 1 and 4
Genotype 2 and 3
Genotype 5 and 6
GGT Levels
Glucose Intolerance
Growth Factors
Guidelines

HCV Clearance
HCV Disease Progression
HCV-Drug Related Adverse Events
HCV Recurrence After Transplantation
Hearing
Hematological Growth Factors
Hemodialysis
Hemoglobin
Hemophilia
Hepatic Decompensation
Hepatic Failure
Hematological Disorders
Hepatocellular Carcinoma
Histology

Hormone Therapies
hyaluronate (HA)
Immunoglobulins
Immunosuppression
Induction Therapy
Injection Drug Use
Infergen
Insulin Resistance
Interferon
Interferon Resistance
Intron A
Kidney Disorders
Kidney Transplant

Liver Biopsy
Liver Enzymes
Liver Issues
Living Donors
Liver Stiffness Measurement (LSM)
Maintenance Therapy
Methadone
Miscellaneous
Mortality and Morbidity

Monotherapy Treatment

Mother to Child Transmission of HCV
Natural History
Neutropenia
Non-Alcoholic Fatty Liver
  Disease (NAFLD)

Non-Hepatic Cancers
Non-Hodgkins Lymphoma
Non-organ Specific Autoantibodies
Nonresponders / Relapsers
Obesity
Occult HBV Infection
Pathogenesis

Pegasys
PEG-Intron
Pegylated Inferferon
Pharmacokinetics
Platelets
Pregnancy
Productivity
PIIINP/MMP-1, prothrombin time (PT)
Quality of Life
Quasispecies
Rapid Virologic Response (RVR)
Recurrent HCV
Re-Treatment
Retinopathy
Ribavirin
Ribavirin Dosing
Risk Factors for HCC
Risk Factors
Roferon
Seroconversion
Sex (gender)
Sexual Transmission
Skin Reactions / Diseases
Sleeplessness
Steatosis
Steroids
Superinfection
Survival
Sustained Viral Response
Toxicities and Side Events
Transmission

Transplantation
Undetectable HCV RNA
Viral Eradication
Viral Kinetics
Viral Load
Weight-based Dosing
Women and Children